Form 4: iTeos Therapeutics CEO Michel Detheux Granted Stock Options
SEC Form 4 Filing
Michel Detheux, CEO of iTeos Therapeutics, acquired stock options for 590,400 shares on March 7, 2024, vesting over four years.
Summary
- Michel Detheux, the CEO of iTeos Therapeutics, Inc., was granted stock options on March 7, 2024.
- The options are for 590,400 shares of common stock.
- The exercise price of the options is $11.58 per share.
- The options vest over four years, with 25% vesting on March 7, 2025, and the remainder vesting in equal monthly installments over the following 36 months, contingent upon continued service to iTeos Therapeutics.
- The expiration date for the options is March 7, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance. The vesting schedule promotes long-term alignment.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the stock options is dependent on the future performance of iTeos Therapeutics' stock price.
- If the CEO leaves the company before the options are fully vested, he will forfeit the unvested portion.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Regeneron also utilize stock options as part of their executive compensation strategy.
- The vesting schedule of four years with monthly installments is a typical structure for stock option grants.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the CEO's interests with theirs.
- Employees may see the grant as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/07/2024 | Date of transaction and grant of stock options. |
| 03/07/2025 | First vesting date (25% of options). |
| 03/07/2034 | Expiration date of the stock options. |
| 03/08/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.